Poolbeg Pharma has received ethics and competent authority approval to commence its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment for severe influenza.
Clinical trial activities formally commenced on July 22, 2022.
The trial will assess the efficacy of POLB 001 in dampening the robust immune response to LPS, which acts as a surrogate for the hyperinflammatory response associated with severe influenza and other diseases.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
